[
  {
    "ts": null,
    "headline": "Transcript : Merck & Co., Inc. Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 06",
    "summary": "Presentation Operator MessageOperator Thank you for standing by. Welcome to the Merck & Co., Inc. New Jersey USA Investor Event at the American Society of Clinical Oncology Annual Meeting.",
    "url": "https://finnhub.io/api/news?id=9971e338c7106a830ac4094881d0725c2c814b7ae57b4e5dce094ca16db664ce",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748900119,
      "headline": "Transcript : Merck & Co., Inc. Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 06",
      "id": 134967750,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Presentation Operator MessageOperator Thank you for standing by. Welcome to the Merck & Co., Inc. New Jersey USA Investor Event at the American Society of Clinical Oncology Annual Meeting.",
      "url": "https://finnhub.io/api/news?id=9971e338c7106a830ac4094881d0725c2c814b7ae57b4e5dce094ca16db664ce"
    }
  },
  {
    "ts": null,
    "headline": "Merck held talks to buy biotech MoonLake for over $3 billion, FT reports",
    "summary": "Merck has held talks to buySwiss biotech MoonLake Immunotherapeutics for more than$3 billion, the Financial Times reported on Monday, citing threepeople familiar with the matter. ...",
    "url": "https://finnhub.io/api/news?id=d7e2fd83b59a27f4e1215c3d7281a0dc82639500ed28a1a8ed9a91e8be3629e4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748885531,
      "headline": "Merck held talks to buy biotech MoonLake for over $3 billion, FT reports",
      "id": 134965312,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck has held talks to buySwiss biotech MoonLake Immunotherapeutics for more than$3 billion, the Financial Times reported on Monday, citing threepeople familiar with the matter. ...",
      "url": "https://finnhub.io/api/news?id=d7e2fd83b59a27f4e1215c3d7281a0dc82639500ed28a1a8ed9a91e8be3629e4"
    }
  },
  {
    "ts": null,
    "headline": "Merck Held Talks To Buy Swiss Biotech Moonlake For More Than $3 Bln- FT",
    "summary": "June 2 - * MERCK HELD TALKS TO BUY SWISS BIOTECH MOONLAKE FOR MORETHAN$3BN- FTSource text: [https://on.ft.com/43pXSbT]Further company coverage: ...",
    "url": "https://finnhub.io/api/news?id=352a24fc63d86a239affedda84ebb114b59b00d9e8d7c5c33f4ad777ae332447",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748883188,
      "headline": "Merck Held Talks To Buy Swiss Biotech Moonlake For More Than $3 Bln- FT",
      "id": 134962787,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "June 2 - * MERCK HELD TALKS TO BUY SWISS BIOTECH MOONLAKE FOR MORETHAN$3BN- FTSource text: [https://on.ft.com/43pXSbT]Further company coverage: ...",
      "url": "https://finnhub.io/api/news?id=352a24fc63d86a239affedda84ebb114b59b00d9e8d7c5c33f4ad777ae332447"
    }
  },
  {
    "ts": null,
    "headline": "MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study",
    "summary": "Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.",
    "url": "https://finnhub.io/api/news?id=97117af335aebe6e07483f7e5e1cbfff98037e0313f415a514755e792f73834d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748875980,
      "headline": "MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study",
      "id": 134955280,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.",
      "url": "https://finnhub.io/api/news?id=97117af335aebe6e07483f7e5e1cbfff98037e0313f415a514755e792f73834d"
    }
  },
  {
    "ts": null,
    "headline": "Are Options Traders Betting on a Big Move in Merck Stock?",
    "summary": "Investors need to pay close attention to MRK stock based on the movements in the options market lately.",
    "url": "https://finnhub.io/api/news?id=e35419a4bf5dee6167827d48c653881b49521a62831a6bcf9ebe452cd05c5320",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748870520,
      "headline": "Are Options Traders Betting on a Big Move in Merck Stock?",
      "id": 134967456,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investors need to pay close attention to MRK stock based on the movements in the options market lately.",
      "url": "https://finnhub.io/api/news?id=e35419a4bf5dee6167827d48c653881b49521a62831a6bcf9ebe452cd05c5320"
    }
  },
  {
    "ts": null,
    "headline": "3M, Caterpillar share losses lead Dow's 150-point fall",
    "summary": "3M, Caterpillar share losses lead Dow's 150-point fall",
    "url": "https://finnhub.io/api/news?id=b23ceb8237d120863ab06e0ff397446499c179b40bde45c9a4a9f90e3a727666",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748869020,
      "headline": "3M, Caterpillar share losses lead Dow's 150-point fall",
      "id": 134982923,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "3M, Caterpillar share losses lead Dow's 150-point fall",
      "url": "https://finnhub.io/api/news?id=b23ceb8237d120863ab06e0ff397446499c179b40bde45c9a4a9f90e3a727666"
    }
  },
  {
    "ts": null,
    "headline": "Put Cash To Work: 2 Magnificent Dividends I'm Betting On",
    "summary": "Discover why RTX & AbbVie are top picks for growth & income.",
    "url": "https://finnhub.io/api/news?id=055adbcc07b3c97a6108e18da5df5139ba8c3f57b9c90f63dc0ab0c36819f5d2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748858400,
      "headline": "Put Cash To Work: 2 Magnificent Dividends I'm Betting On",
      "id": 134939270,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover why RTX & AbbVie are top picks for growth & income.",
      "url": "https://finnhub.io/api/news?id=055adbcc07b3c97a6108e18da5df5139ba8c3f57b9c90f63dc0ab0c36819f5d2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
    "summary": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
    "url": "https://finnhub.io/api/news?id=5ef7be33f4137c957a17b7a3964798438424975eb58ff3ed5ee5bf0d171506d7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748853960,
      "headline": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
      "id": 134941480,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
      "url": "https://finnhub.io/api/news?id=5ef7be33f4137c957a17b7a3964798438424975eb58ff3ed5ee5bf0d171506d7"
    }
  },
  {
    "ts": null,
    "headline": "2 Dirt Cheap Dividend Stocks That Are Practically Giving Themselves Away",
    "summary": "I stick to quality dividend stocks. Find out why and learn more about two high-conviction dividend stocks that the market is underpricing.",
    "url": "https://finnhub.io/api/news?id=b0d0cd4c49f33b9be18a5f2b79d08bf898ed500c9b62f7b4592d7f3c3a3334a3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748849400,
      "headline": "2 Dirt Cheap Dividend Stocks That Are Practically Giving Themselves Away",
      "id": 134936245,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316534843/image_1316534843.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "I stick to quality dividend stocks. Find out why and learn more about two high-conviction dividend stocks that the market is underpricing.",
      "url": "https://finnhub.io/api/news?id=b0d0cd4c49f33b9be18a5f2b79d08bf898ed500c9b62f7b4592d7f3c3a3334a3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers signs deal worth up to $11.1 billion with BioNTech to develop cancer drug",
    "summary": "Bristol Myers Squibb hasagreed to pay up to $11.1 billion in a partnership withGermany's BioNTech to develop the latter'snext-generation cancer immunotherapy that could take on rivalMerck & Co's...",
    "url": "https://finnhub.io/api/news?id=eabb286bba1b1d596ff1d37c51c9a5d85c82d2ad430088d85cbc37995152e054",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748846789,
      "headline": "Bristol Myers signs deal worth up to $11.1 billion with BioNTech to develop cancer drug",
      "id": 134938559,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb hasagreed to pay up to $11.1 billion in a partnership withGermany's BioNTech to develop the latter'snext-generation cancer immunotherapy that could take on rivalMerck & Co's...",
      "url": "https://finnhub.io/api/news?id=eabb286bba1b1d596ff1d37c51c9a5d85c82d2ad430088d85cbc37995152e054"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership",
    "summary": "Bristol Myers Squibb will pay$1.5 billion upfront to partner with Germany's BioNTechon an experimental cancer drug, the U.S.company said on Monday, in a deal that could eventually exceed$11...",
    "url": "https://finnhub.io/api/news?id=73e4e97e097b95b48b8b5d49b0631be93138ddd5e0dab9172eb882faec0559a1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748846789,
      "headline": "Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership",
      "id": 134936054,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb will pay$1.5 billion upfront to partner with Germany's BioNTechon an experimental cancer drug, the U.S.company said on Monday, in a deal that could eventually exceed$11...",
      "url": "https://finnhub.io/api/news?id=73e4e97e097b95b48b8b5d49b0631be93138ddd5e0dab9172eb882faec0559a1"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers allies with BioNTech on bispecific cancer drug",
    "summary": "The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following Merck, and Pfizer into what’s become a competitive development race.",
    "url": "https://finnhub.io/api/news?id=e161f7c047a2d7a9601f41485f9806288293a68aeb689d9be79c28e13d2defa2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748846700,
      "headline": "Bristol Myers allies with BioNTech on bispecific cancer drug",
      "id": 134937149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following Merck, and Pfizer into what’s become a competitive development race.",
      "url": "https://finnhub.io/api/news?id=e161f7c047a2d7a9601f41485f9806288293a68aeb689d9be79c28e13d2defa2"
    }
  },
  {
    "ts": null,
    "headline": "Merck - KEYTRUDA plus Trodelvy Reduced Risk of Disease Progression or Death by 35% versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer",
    "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that KEYTRUDA plus Trodelvy reduced the risk of disease progression or death by 35% (HR=0.65, p 2025 Electronic...",
    "url": "https://finnhub.io/api/news?id=cf6b792e096d5e8ca45093ddb99296a7fa04c8d2dffa3bf99b086f8793aa5204",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748843653,
      "headline": "Merck - KEYTRUDA plus Trodelvy Reduced Risk of Disease Progression or Death by 35% versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer",
      "id": 134935590,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that KEYTRUDA plus Trodelvy reduced the risk of disease progression or death by 35% (HR=0.65, p 2025 Electronic...",
      "url": "https://finnhub.io/api/news?id=cf6b792e096d5e8ca45093ddb99296a7fa04c8d2dffa3bf99b086f8793aa5204"
    }
  }
]